Evidence map›Paper›PMID 39508104›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2025

ApoE Receptor-2 R952Q Variant in Macrophages Elevates Soluble LRP1 to Potentiate Hyperlipidemia and Accelerate Atherosclerosis in Mice.

Vanessa Turkson, April Haller, Anja Jaeschke, David Y Hui

Abstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Tale of 2 Receptors.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Vanessa TurksonDepartment of Pharmacology and Systems Physiology (V.T.), University of Cincinnati College of Medicine, OH.ORCID 0000-0003-3403-9942
April HallerDepartment of Pathology and Laboratory Medicine (A.H., A.J., D.Y.H.), University of Cincinnati College of Medicine, OH.
Anja JaeschkeDepartment of Pathology and Laboratory Medicine (A.H., A.J., D.Y.H.), University of Cincinnati College of Medicine, OH.
David Y HuiDepartment of Pathology and Laboratory Medicine (A.H., A.J., D.Y.H.), University of Cincinnati College of Medicine, OH.ORCID 0000-0001-7333-2151

Funding

ApoE receptor-2 in vascular disease progression and regressionR01HL147403 · NHLBI · UNIVERSITY OF CINCINNATI · PI HUI, DAVID YIU-KWAN · 2019 to 2022
$3.0M
Polymorphic ApoE at the crossroad of lipid metabolism and inflammation in atherosclerosisR01HL156954 · NHLBI · UNIVERSITY OF CINCINNATI · PI HUI, DAVID YIU-KWAN · 2022 to 2025
$2.4M
NHLBI NIH HHS R01 HL147403NHLBI NIH HHS R01 HL156954
6 · The paper itself

Abstract

backgroundapoER2 (apolipoprotein E receptor-2) is a transmembrane receptor in the low-density lipoprotein receptor (LDLR) family with unique tissue expression. A single-nucleotide polymorphism that encodes the R952Q sequence variant has been associated with elevated plasma cholesterol levels and increased myocardial infarction risk in humans. The objective of this study was to delineate the mechanism underlying the association between the apoER2 variant with arginine-to-glutamine substitution at residue 952 (R952Q) and increased atherosclerosis risk.

methodsAn apoER2 R952Q mouse model was generated and intercrossed with LDLR knockout mice, followed by feeding a Western-type high-fat high-cholesterol diet for 16 weeks. Atherosclerosis was investigated by immunohistology. Plasma lipids and lipid distributions among the various lipoprotein classes were analyzed by colorimetric assay. Tissue-specific effects of the R952Q sequence variant on atherosclerosis were analyzed by bone marrow transplant studies. sLRP1 (soluble low-density lipoprotein receptor-related protein 1) was measured in plasma and conditioned media from bone marrow-derived macrophages by ELISA and GST-RAP (glutathione S-transferase-receptor-associated protein) pull-down, respectively. P38 MAPK (mitogen-activated protein kinase) phosphorylation in VLDL (very-low-density lipoprotein)-treated macrophages was determined by Western blot analysis.

resultsConsistent with observations in humans with this sequence variant, the apoER2 R952Q mutation exacerbated diet-induced hypercholesterolemia, via impediment of plasma triglyceride-rich lipoprotein clearance, to accelerate atherosclerosis in Western diet-fed LDLR knockout mice. Reciprocal bone marrow transplant experiments revealed that the apoER2 R952Q mutation in bone marrow-derived cells instead of non-bone marrow-derived cells was responsible for the increase in hypercholesterolemia and atherosclerosis. Additional data showed that the apoER2 R952Q mutation in macrophages promotes VLDL-induced LRP1 (low-density lipoprotein receptor-related protein 1) shedding in a p38 MAPK-dependent manner.

conclusionsThe apoER2 R952Q mouse model recapitulates characteristics observed in human disease. The underlying mechanism is that the apoER2 R952Q mutation in macrophages exacerbates VLDL-stimulated sLRP1 production in a p38 MAPK-dependent manner, resulting in its competition with cell surface LRP1 to impede triglyceride-rich lipoprotein clearance, thereby resulting in increased hypercholesterolemia and accelerated atherosclerosis.

Indexed as

AtherosclerosisDisease Models, AnimalHyperlipidemiasLow Density Lipoprotein Receptor-Related Protein-1MacrophagesMice, Inbred C57BLMice, Knockoutp38 Mitogen-Activated Protein KinasesReceptors, LDLAnimalsAortic DiseasesBone Marrow TransplantationCells, CulturedDiet, High-FatGenetic Predisposition to DiseaseMaleLow Density Lipoprotein Receptor-Related Protein-1Lrp1 protein, mousep38 Mitogen-Activated Protein KinasesReceptors, LDLatherosclerosiscoronary artery diseasehypercholesterolemiaLDL receptor-related proteins

Identifiers

PMID39508104
PMCPMC11668615

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.